GUD.TO vs. FTS.TO
GUD.TO (Knight Therapeutics Inc.) and FTS.TO (Fortis Inc.) are both stocks. GUD.TO operates in Drug Manufacturers - Specialty & Generic (Healthcare), while FTS.TO operates in Utilities - Regulated Electric (Utilities). Over the past 10 years, GUD.TO returned -0.35%/yr vs 10.42%/yr for FTS.TO. At a 0.10 correlation, their price movements are largely independent.
Performance
GUD.TO vs. FTS.TO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GUD.TO achieves a 37.36% return, which is significantly higher than FTS.TO's 8.30% return. Over the past 10 years, GUD.TO has underperformed FTS.TO with an annualized return of -0.35%, while FTS.TO has yielded a comparatively higher 10.42% annualized return.
GUD.TO
- 1D
- 1.34%
- 1M
- 10.07%
- YTD
- 37.36%
- 6M
- 37.58%
- 1Y
- 43.28%
- 3Y*
- 19.42%
- 5Y*
- 9.58%
- 10Y*
- -0.35%
FTS.TO
- 1D
- 0.38%
- 1M
- -1.12%
- YTD
- 8.30%
- 6M
- 8.41%
- 1Y
- 18.40%
- 3Y*
- 13.98%
- 5Y*
- 10.73%
- 10Y*
- 10.42%
GUD.TO vs. FTS.TO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GUD.TO Knight Therapeutics Inc. | 37.36% | 13.30% | 2.89% | 0.19% | -2.26% | -0.93% | -29.42% | -1.43% | -7.46% | -22.63% |
FTS.TO Fortis Inc. | 8.30% | 23.93% | 14.24% | 4.76% | -7.87% | 21.81% | 0.04% | 22.71% | 2.74% | 15.29% |
Correlation
The correlation between GUD.TO and FTS.TO is -0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.01 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.07 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.09 |
Correlation (All Time) Calculated using the full available price history since Mar 4, 2014 | 0.10 |
The correlation between GUD.TO and FTS.TO shifts across timeframes, from -0.01 (1 year) to 0.10 (all time), reflecting how their relationship changes across market environments.
Fundamentals
GUD.TO:
CA$822.08M
FTS.TO:
CA$38.65B
GUD.TO:
CA$0.06
FTS.TO:
CA$3.56
GUD.TO:
147.17
FTS.TO:
21.33
GUD.TO:
1.62
FTS.TO:
3.15
GUD.TO:
1.04
FTS.TO:
1.70
GUD.TO:
CA$510.45M
FTS.TO:
CA$12.21B
GUD.TO:
CA$190.52M
FTS.TO:
CA$3.98B
GUD.TO:
CA$65.18M
FTS.TO:
CA$5.87B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GUD.TO vs. FTS.TO — Risk / Return Rank
GUD.TO
FTS.TO
GUD.TO vs. FTS.TO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Knight Therapeutics Inc. (GUD.TO) and Fortis Inc. (FTS.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GUD.TO | FTS.TO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.38 | ||
| Sortino ratioReturn per unit of downside risk | +1.05 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.26 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 3.60 | 3.04 | +0.56 |
| Martin ratioReturn relative to average drawdown | 6.88 | 7.25 | -0.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GUD.TO | FTS.TO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.81 | 1.43 | +0.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.40 | 0.75 | -0.35 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.01 | 0.62 | -0.64 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.24 | 0.65 | -0.40 |
Drawdowns
GUD.TO vs. FTS.TO - Drawdown Comparison
The maximum GUD.TO drawdown since its inception was -60.09%, which is greater than FTS.TO's maximum drawdown of -35.48%. Use the drawdown chart below to compare losses from any high point for GUD.TO and FTS.TO.
Loading charts...
Drawdown Indicators
| GUD.TO | FTS.TO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -60.09% | -35.48% | -24.61% |
Max Drawdown (1Y)Largest decline over 1 year | -12.08% | -6.09% | -5.99% |
Max Drawdown (3Y)Largest decline over 3 years | -17.58% | -11.22% | -6.36% |
Max Drawdown (5Y)Largest decline over 5 years | -29.61% | -24.01% | -5.60% |
Max Drawdown (10Y)Largest decline over 10 years | -60.09% | -28.27% | -31.82% |
Current DrawdownCurrent decline from peak | -23.76% | -4.32% | -19.44% |
Average DrawdownAverage peak-to-trough decline | -34.49% | -6.52% | -27.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.31% | 2.63% | +3.68% |
Volatility
GUD.TO vs. FTS.TO - Volatility Comparison
Knight Therapeutics Inc. (GUD.TO) has a higher volatility of 13.15% compared to Fortis Inc. (FTS.TO) at 4.84%. This indicates that GUD.TO's price experiences larger fluctuations and is considered to be riskier than FTS.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GUD.TO | FTS.TO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.15% | 4.84% | +8.31% |
Volatility (6M)Calculated over the trailing 6-month period | 19.93% | 10.39% | +9.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.01% | 12.93% | +11.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.04% | 14.41% | +9.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.08% | 16.84% | +7.24% |
Dividends
GUD.TO vs. FTS.TO - Dividend Comparison
GUD.TO has not paid dividends to shareholders, while FTS.TO's dividend yield for the trailing twelve months is around 3.34%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
FTS.TO Fortis Inc. | 3.34% | 3.48% | 3.99% | 4.19% | 4.01% | 3.36% | 3.73% | 3.39% | 3.79% | 3.52% | 3.68% | 3.73% |
GUD.TO Knight Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
GUD.TO vs. FTS.TO - Financials Comparison
This section allows you to compare key financial metrics between Knight Therapeutics Inc. and Fortis Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GUD.TO vs. FTS.TO - Profitability Comparison
GUD.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Knight Therapeutics Inc. reported a gross profit of 54.44M and revenue of 148.44M. Therefore, the gross margin over that period was 36.7%.
FTS.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Fortis Inc. reported a gross profit of 933.00M and revenue of 3.38B. Therefore, the gross margin over that period was 27.6%.
GUD.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Knight Therapeutics Inc. reported an operating income of 10.58M and revenue of 148.44M, resulting in an operating margin of 7.1%.
FTS.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Fortis Inc. reported an operating income of 933.00M and revenue of 3.38B, resulting in an operating margin of 27.6%.
GUD.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Knight Therapeutics Inc. reported a net income of 13.17M and revenue of 148.44M, resulting in a net margin of 8.9%.
FTS.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Fortis Inc. reported a net income of 523.00M and revenue of 3.38B, resulting in a net margin of 15.5%.
Frequently Asked Questions
GUD.TO and FTS.TO have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GUD.TO and FTS.TO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer